DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.
You may also be interested in...
AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track
Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.
AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track
Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.
DOV Out-Licenses Pain Candidate Bicifadine To XTL
XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.